Thyroid Hurthle cell carcinoma

This phase 2 trial tests a drug called XL092 in 33 people with advanced thyroid cancer that has stopped responding to radioiodine therapy. XL092 works by blocking a protein that helps cancer cells grow. The study aims to see if the drug can slow or stop cancer progression.

This phase 2 trial is testing whether giving the drug pembrolizumab before thyroid surgery can help the immune system attack high-risk differentiated thyroid cancer. About 25 adults with a high chance of cancer returning will receive two doses of pembrolizumab before their thyroi…

This phase 2 trial tests whether two targeted drugs, vemurafenib and cobimetinib, can make thyroid cancer cells more responsive to radioactive iodine therapy. The study enrolls 21 adults with high-risk, BRAF-mutated thyroid cancer who have not yet received radioactive iodine. Par…

This study tests whether a special PET scan using a radioactive tracer called 68Gallium-DOTATATE can better detect thyroid cancer that has spread and no longer responds to standard radioactive iodine therapy. About 54 adults with metastatic thyroid cancer will receive one injecti…

This study is for people who have or might have a thyroid nodule or thyroid cancer. Researchers want to learn more about how to diagnose and treat these conditions. Participants will have standard medical tests like blood draws and scans, plus some extra research tests. The goal …